news & meetings - latest announcements & happenings | oneGRAVESvoice

welcome to oneGRAVESvoice

- a positively charged Graves' disease and thyroid eye disease community.
  • join today!
Most Graves’ Disease Treated With Antithyroid Drugs
Clinical Trials And Research

Most Graves’ Disease Treated With Antithyroid Drugs

Adults with Graves’ disease are more likely to receive drug treatment — despite a higher failure rate — than radioactive iodine therapy or thyroid surgery, according to findings published in Thyroid.

“We are noticing that more people with Graves’ disease are treated with antithyroid drugs than radioactive iodine or surgery; and one fourth of people treated with antithyroid drugs will receive it as long-term — more than 2 years,” Juan P. Brito, MD, MSc, principal investigator for the Knowledge and Evaluation Research Unit in Endocrinology in the division of endocrinology, diabetes, metabolism and nutrition of the department of medicine at Mayo Clinic in Rochester, Minnesota, told Healio. “A significant number of people with Graves’ disease are receiving antithyroid drugs chronically. This way of treatment was known in other countries, particularly in Asia, but unknown here in the U.S.”

 

Mar 12, 2020
The New England Journal Of Medicine Publishes Comprehensive Data From Phase 3 Clinical Trial (OPTIC) Of TEPEZZA™ (Teprotumumab-Trbw) For Thyroid Eye Disease
Clinical Trials And Research

The New England Journal of Medicine Publishes Comprehensive Data From Phase 3 Clinical Trial (OPTIC) of TEPEZZA™ (Teprotumumab-Trbw) for Thyroid Eye Disease

Horizon Therapeutics plc announced that The New England Journal of Medicine has published comprehensive results of the Phase 3 OPTIC clinical trial evaluating TEPEZZA™ (teprotumumab-trbw) for Thyroid Eye Disease (TED). OPTIC is part of the largest clinical program in TED and demonstrates that TEPEZZA provides significant improvements in proptosis (eye bulging) and diplopia (double vision) compared to placebo.

TEPEZZA is a fully human monoclonal antibody (mAb) and a targeted inhibitor of the insulin-like growth factor-1 receptor (IGF-1R) that is administered to patients once every three weeks for a total of eight infusions. TEPEZZA was approved by the U.S. Food and Drug Administration (FDA) on January 21, 2020 – making it the first and only medicine approved for the treatment of TED. The medicine received Priority Review, Orphan Drug, Fast Track and Breakthrough Therapy designations from the FDA.

 

More from Teprotumumab News:

FDA Approves First Treatment for Thyroid Eye Disease (Teprotumumab)

Teprotumumab Significantly Improves Proptosis in Thyroid eye Disease

Clinical Trial Analyses Substantiate that Teprotumumab Improves Debilitating Effects of TED

FDA Grants Priority Review of Teprotumumab Biologics License Application for the Treatment of TED

 

More from Teprotumumab Research:

Teprotumumab for the Treatment of Active Thyroid Eye Disease

(Authors: Raymond S. Douglas, George J. Kahaly et. al.)

 

Teprotumumab in the Treatment of Active TED: A Focus on Proptosis

(Author: Raymond S. Douglas)

Jan 22, 2020
    Font Resize

    To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
    More information

    The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

    Close